You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Oligonucleotide Enzyme Surrogate (OnES)

    SBC: Accacia International LLC            Topic: CBD08108

    Historically organophosphorus compounds such as insecticides and nerve agents have been susceptible to decomposition by proteinaceous enzymes. Organophosphate hydrolases (OPH) represent a practical method to deactivate such compounds peripherally and on surfaces. However, when such organophosphates are ingested, the use of proteinaceous enzymes such as OPH can be problematic because of their tende ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  2. SBIR PHASE I, TOPIC 239 HIGH-THROUGHPUT SELECTION OF APTAMERS AGAINST CANCER BIOM

    SBC: Accacia International LLC            Topic: N/A

    N/A

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. T7 RNA polymerase engineering and RNA amplification

    SBC: Accacia International LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Expanding use of microarray systems for global gene expression profiling is leading biological research, providing diagnostic and prognostic value to physicians and facilitating target discovery during drug and vaccine development. There is strong interest in extending this microarray capability to more RNA-limited material to the point that a single cell can b ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Lightweight, Durable, Adjustable Composite Backrest

    SBC: ACCESSIBLE DESIGNS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): We have designed a prototype lightweight, sturdy, user adjustable ergonomically designed backrest support for ultralight weight wheelchairs that will provide necessary postural support and provide a variety of positions to ease dressing, propulsion, and seated comfort. The backrest will improve user comfort, function, and posture during multiple activities of ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. Carbon Nanotube-Based Filters for Aerosol Sample Collection

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD07111

    Aerosols represent one of the more efficient methods to distribute biological and chemical agents throughout the atmosphere. Small aerosol droplets can be readily inhaled and easily penetrate deep into the lungs where they lodge in bronchial alveoli. Within the alveoli, chemical and biological agents can breach epithelial and endothelial cell layers and enter the bloodstream, where they cause da ...

    SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
  6. Multiplex Lyme Disease Diagnostic

    SBC: AGAVE BIOSYSTEMS INC.            Topic: N/A

    DESCRIPTION (provided by investigator): Lyme disease, caused by the gram-negative spirochete Borrelia burgdorferi and transmitted by Ixodid tick species, is the leading vector-borne infectious disease in the United States, with a steady rise in the number of cases reported each year. The most common Lyme disease symptom, the classic bull's-eye rash (erythema migrans or EM rash) in endemic areas, ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  7. Ribozymes for In Vivo Degradation of G-Nerve Agents

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08108

    Given the possibility to administer prophylactic doses of protein bioscavengers inactivating OP nerve agents before they reach their acetylcholinesterase target, much attention has been given to proteins such as human butyrylcholinesterase and paraoxonase I. As small nucleic acid catalysts can exhibit triphosphoesterase activities, the identification of new molecules active against nerve agents w ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  8. Collective Protection for Military Working Dogs

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08103

    Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs. The overall operational weight of th ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  9. Treatment of Sepsis with Talactoferrin

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Severe sepsis is a major cause of morbidity and mortality throughout the world. It is the leading cause of death in non-coronary intensive care units (ICUs) in the United States, with more than 750,000 cases occurring e very year. This means that in the United States, more than 500 patients die from severe sepsis every day, with 28% to 50% of the patients succu ...

    SBIR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Lactoferrin Enhances Growth and Reduces Nosocomial Infection in Preterm Infants

    SBC: AGENNIX, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project aims to develop talactoferrin (TLF, recombinant human lactoferrin) as a therapeutic agent to treat prematurely born neonates. The treatment will be given orally shortly after birth to prevent nosocomial inf ections (NIs) due to abnormal bacterial invasion of neonatal intestinal epithelia and consequently to limit systemic bacteremia and necrotizing ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government